CD79A and COVID-19: On both platforms, the assays measuring total antibody performed better than IgG, IgA or IgM specific assays in discriminating between samples from COVID-19 cases and pre-pandemic donors in the threshold sample set, and thus the four total antibody assays (N Pan, RBD Pan and Spike Pan ELISAs, and the Spike-RBD Bridging LIPS assay) were selected for validation as potential screening assays using a large, blinded validation set from pre-pandemic donors and confirmed/suspected COVID-19 cases.